\
&
Contact us
Background stories of how others approached and experienced their European Horizon funding trajectory.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for detailsPublished on • 1 year ago
These testimonials share at least one programme in common.
Funded under Horizon Europe (HORIZON-CL5-2022-D5-01-02), running from 2023 to 2026, AENEAS advanced the development of innovative electric energy storage solutions tailored for waterborne transport. The project has also created tools & platforms to support the optimal integration of new energy storage systems into vessels, assess their impact on overall system efficiency, and quantify potential reductions in greenhouse gas emissions. The project consortium, led by Flanders Make, consists of 14 partners from 8 countries. Read more about the project in this testimonial.